| Expression pattern: |
DN |
| Associated gene: |
p53, MDM2, AGO2, Dicer |
| Associated microRNA: |
miR-7 |
| Biological function: |
Tumor suppressor in glioma/GBM: inhibits tumor growth, proliferation and colony formation; promotes G0/G1 arrest and apoptosis; protects cells from DNA damage. |
| Molecular mechanism: |
CDR1as directly binds p53 (DBD domain), disrupts p53/MDM2 complex formation, inhibits MDM2-mediated ubiquitination and degradation of p53, thereby stabilizing p53 protein (independent of miRNA sponge activity). |
| Biological pathway or process: |
p53 signaling (promotes); proliferation (inhibits); cell cycle (inhibits); apoptosis (promotes); other pathway/process (other) |
| Detected method: |
Q
H
S
|
| Validation methods: |
RIP (RNA Immunoprecipitation); RNA-seq; RT-qPCR; FISH / smFISH; IF (Immunofluorescence); circRIP; RNA Pull-Down; Western Blot; Co-IP; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis; ROC Analysis; Bioinformatics Analysis; Clinical Sample Validation; Cohort Study |
| Clinical significance: |
CDR1as is an independent predictor of overall survival in glioma/GBM; lower expression in higher WHO grade; positively correlated with overall survival; AUC > 0.7 for predicting hazard rate. |
| Description: |
CDR1as is down-regulated in glioma/GBM and acts as a tumor suppressor. It binds p53 (via the DBD), disrupts p53/MDM2 complex formation, reduces p53 ubiquitination, stabilizes p53 protein and enhances p53 pathway activity, leading to reduced glioma cell growth and increased cell-cycle arrest/apoptosis, including under DNA damage. |
| Confidence score: |
0.8424 |